{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:10:29Z","timestamp":1793920229728,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-023-00816-1","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:01:40Z","timestamp":1696676500000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for \u2265\u00a0156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct02207231","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M. G. J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wapenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gorecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Gramiccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"issue":"19","key":"816_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"A Armstrong","year":"2020","unstructured":"Armstrong A, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"12","key":"816_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537\u201341.","journal-title":"Arch Dermatol"},{"issue":"3","key":"816_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"816_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","volume":"186","author":"L Puig","year":"2022","unstructured":"Puig L, Costanzo A, Munoz-Elias EJ, Jazra M, Wegner S, Paul CF, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022;186(5):773\u201381.","journal-title":"Br J Dermatol"},{"issue":"3","key":"816_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jdv.17829","volume":"36","author":"I van Ee","year":"2022","unstructured":"van Ee I, Deprez E, Egeberg A, Augustin M, Conrad C, Corazza V, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022;36(3):403\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"816_CR6","first-page":"247","volume":"17","author":"KA Papp","year":"2018","unstructured":"Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17(3):247\u201350.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"816_CR7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/bjd.16140","volume":"178","author":"RB Warren","year":"2018","unstructured":"Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064\u201371.","journal-title":"Br J Dermatol"},{"issue":"3","key":"816_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"816_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clindermatol.2009.03.002","volume":"28","author":"C Ferr\u00e1ndiz","year":"2010","unstructured":"Ferr\u00e1ndiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol. 2010;28(1):81\u20137.","journal-title":"Clin Dermatol"},{"key":"816_CR10","unstructured":"ClinicalTrials.gov. A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis (NCT02207231). 2015 [cited 2022 August 30]; https:\/\/ClinicalTrials.gov\/show\/NCT02207231"},{"issue":"6","key":"816_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"816_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"1","key":"816_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"6","key":"816_CR14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358.","journal-title":"Br J Dermatol"},{"issue":"6","key":"816_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13964","volume":"33","author":"I Snast","year":"2020","unstructured":"Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964.","journal-title":"Dermatol Ther"},{"issue":"4","key":"816_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15339","volume":"35","author":"A Michelucci","year":"2022","unstructured":"Michelucci A, Manzo Margiotta F, Panduri S, Tonini A, Romanelli M, Morganti R, et al. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022;35(4):e15339.","journal-title":"Dermatol Ther"},{"key":"816_CR17","first-page":"205","volume":"12","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205\u201312.","journal-title":"Psoriasis (Auckl)."},{"issue":"7","key":"816_CR18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/jcm9072170","volume":"9","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.","journal-title":"J Clin Med"},{"issue":"12","key":"816_CR19","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/1346-8138.16128","volume":"48","author":"S Gerdes","year":"2021","unstructured":"Gerdes S, Brau B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854\u201362.","journal-title":"J Dermatol"},{"issue":"12","key":"816_CR20","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1080\/14712598.2022.2064216","volume":"22","author":"F Bardazzi","year":"2022","unstructured":"Bardazzi F, Viviani F, Merli Y, Di Lernia V, Peccerillo F, Conti A, et al. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opin Biol Ther. 2022;22(12):1561\u20136.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"816_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"key":"816_CR22","unstructured":"National Institute for Health and Care Excellence. Guselkumab for treating moderate to severe plaque psoriasis (TA521). 2018 [cited 2022 August 30]; http:\/\/www.nice.org.uk\/guidance\/ta521."},{"issue":"1","key":"816_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235\u201352.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"816_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"816_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"816_CR26","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/jdv.15668","volume":"33","author":"M Lebwohl","year":"2019","unstructured":"Lebwohl M, Langley RG, Zhu Y, Zhou H, Song M, Shen YK, et al. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(11):2082\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"816_CR27","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1111\/jdv.16265","volume":"34","author":"B Husson","year":"2020","unstructured":"Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahe E, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"816_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bjd.18327","volume":"182","author":"S Hsu","year":"2020","unstructured":"Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol. 2020;182(4):880\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"816_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bjd.16008","volume":"178","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132\u20139.","journal-title":"Br J Dermatol"},{"key":"816_CR30","doi-asserted-by":"crossref","first-page":"204062232110466","DOI":"10.1177\/20406223211046685","volume":"12","author":"YT Hung","year":"2021","unstructured":"Hung YT, Lin YJ, Chiu HY, Huang YH. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv Chron Dis. 2021;12:20406223211046684.","journal-title":"Ther Adv Chron Dis."},{"issue":"5","key":"816_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jcph.1063","volume":"58","author":"Z Yao","year":"2018","unstructured":"Yao Z, Hu C, Zhu Y, Xu Z, Randazzo B, Wasfi Y, et al. Population pharmacokinetic modeling of guselkumab, a human IgG1\u03bb monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58(5):613\u201327.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"816_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/cts.13197","volume":"15","author":"Y Chen","year":"2021","unstructured":"Chen Y, Miao X, Hsu CH, Zhuang Y, Kollmeier A, Xu Z, et al. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. Clin Transl Sci. 2021;15(3):749\u201360.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"816_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15378","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Susca S, Megna M, Siliquini N, Quaglino P, Ortoncelli M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35(5): e15378.","journal-title":"Dermatol Ther"},{"issue":"2","key":"816_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162\u201375.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"816_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31\u201355.","journal-title":"Immunity"},{"key":"816_CR36","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management. Clinical Guideline (CG153). 2012 cited; https:\/\/www.nice.org.uk\/guidance\/cg153"},{"key":"816_CR37","doi-asserted-by":"crossref","unstructured":"Kreuger J, Eyerich K, Greving C, Sachen K, Hammaker D, Bao P, et al. Differentiation of therepeutic antibodies targetting IL-23. Presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting. AAD Anual Meeting, May 18\u201321; 2022.","DOI":"10.1016\/j.jid.2022.05.1013"},{"issue":"1","key":"816_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","volume":"20","author":"AW Armstrong","year":"2019","unstructured":"Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, et al. Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol. 2019;20(1):155\u201364.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"816_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"816_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"816_CR41","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1080\/09546634.2021.1898528","volume":"33","author":"SR Feldman","year":"2022","unstructured":"Feldman SR, Merola JF, Pariser DM, Zhang J, Zhao Y, Mendelsohn AM, et al. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2022;33(3):1670\u20135.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"816_CR42","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1111\/jdv.16400","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, et al. Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. J Eur Acad Dermatol Venereol. 2020;34(11):2548\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"816_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, Schakel K, Asadullah K, Wegner S, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9):e049822.","journal-title":"BMJ Open"},{"issue":"10","key":"816_CR44","doi-asserted-by":"publisher","first-page":"300060520964024","DOI":"10.1177\/0300060520964024","volume":"48","author":"H Zhou","year":"2020","unstructured":"Zhou H, Wu R, Kong Y, Zhao M, Su Y. Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis. J Int Med Res. 2020;48(10):300060520964024.","journal-title":"J Int Med Res"},{"issue":"4","key":"816_CR45","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1159\/000520290","volume":"238","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab is associated with high rates of complete clearance and quality of life improvement: a subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology. 2022;238(4):620\u20139.","journal-title":"Dermatology"},{"issue":"3","key":"816_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. 2015;26(3):235\u20139.","journal-title":"J Dermatol Treat"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00816-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00816-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00816-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:12:58Z","timestamp":1707973978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00816-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00816-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"22 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was sponsored by Janssen. Medical writing and editorial support were funded by Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LP reports consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Samsung-Bioepis, and UCB; payment or honoraria from Janssen, Lilly, Novartis, and UCB; support for attending meetings and\/or travel from Janssen and UCB; grants received from Abbvie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB; and a non-financial relationship with the International Psoriasis Council. AC reports consulting fees from AbbVie and UCB; payment or honoraria from AbbVie, Almirall, Amgen, Galderma, Janssen, Lilly, Novartis, and UCB; support for attending meetings and\/or travel from AbbVie; and participation on a Data Safety Monitoring Board and\/or Advisory Board for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB. EMGJdJ reports receiving research grants from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, and UCB; and has acted as a consultant, paid speaker, and\/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Galapagos, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, Sanofi, and UCB. TT reports consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sandoz, and Sanofi; support for attending meetings and\/or travel from AbbVie, Almirall, Janssen, Leo Pharma, MSD, Novartis, Pfizer, and Sanofi; and participation on a Data Safety Monitoring Board and\/or Advisory Board for Samsung-Bioepis. RBW reports consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB; and grants received from AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB. RW holds stock at Johnson & Johnson and was a full-time employee of Janssen at the time of the study. SW is a full-time employee of and owns stock at Janssen. PG is a full-time employee at Janssen. TG is a full-time employee at Janssen. MJ holds stocks at Johnson & Johnson and is a full-time employee at Janssen. JB is a full-time employee at Janssen. CC reports consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB; payment or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB; participation on a Data Safety Monitoring Board and\/or Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, MSD, Novartis, Pfizer, and UCB; grants received from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, and Pfizer; and leadership and\/or fiduciary roles for the European Society for Dermatological Research and the Swiss Society for Dermatology and Venereology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Given that this is a post-hoc analysis of the VOYAGE 1 clinical trial, ethical approval was not needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation\/termination conditions, and risks and benefits of treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"LP, AC, TT, RBW, RW, SW, PG, TG, MJ, and CC contributed to conceptualization of the study; TT, RW, SW, PG, MJ, and CC contributed to the development and design of the methodology; TT, SW, and JB contributed to the data curation; TT, RW, and JB contributed to formal data analysis; SW, PG, and MJ provided funding acquisition and financial support for the project; LP, TT, PG, and CC conducted the research; RBW, SW, PG, MJ, and CC planned, directed, and coordinated research activity; PG provided resources and analysis tools; RW contributed to the programming and implementation of computer programs; AC, TT, RBW, SW, PG, and MJ provided supervision of the research, including mentorship; AC, TT, SW, PG, MJ, and JB provided validation of the results; LP, AC, TT, SW, MJ, JB, and CC contributed to data visualization and presentation; SW, PG, and TG contributed to writing the initial draft of the manuscript; LP, AC, EMGJdJ, TT, RBW, RW, SW, PG, TG, JB, and CC provided critical review at each stage the manuscript\u2019s development. All authors approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}